Cited by

• Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized study.

  Fenaux P, Gobbi M, Kropf PL, Issa JJ, Roboz GJ, Mayer J, Krauter J, Robak T, Kantarjian H, Novak J, Jedrzejczak WW, Thomas X, Ojeda-Uribe M, Miyazaki Y, Min YH, Yeh SP, Brandwein J, Gercheva-Kyuchukova L, Demeter J, Griffiths E, Yee K, Döhner K, Hao Y, Keer H, Azab M, Döhner H. Fenaux P, et al. Blood Adv. 2023 Sep 12;7(17):5027-5037. doi: 10.1182/bloodadvances.2023010179. Blood Adv. 2023. PMID: 37276510 Free PMC article. Clinical Trial.
• Management of patients with lower-risk myelodysplastic syndromes.

  Brunner AM, Leitch HA, van de Loosdrecht AA, Bonadies N. Brunner AM, et al. Blood Cancer J. 2022 Dec 14;12(12):166. doi: 10.1038/s41408-022-00765-8. Blood Cancer J. 2022. PMID: 36517487 Free PMC article. Review.
• A treatment-refractory aggressive MDS-MLD with multiple highly complex chromosome 5 intrachromosomal rearrangements: a case report.

  Sasi R, Senft J, Spruill M, Barua S, Dougaparsad S, Vos JA, Perrotta PL. Sasi R, et al. Mol Cytogenet. 2022 Dec 6;15(1):51. doi: 10.1186/s13039-022-00630-0. Mol Cytogenet. 2022. PMID: 36474285 Free PMC article.
• Myelodysplastic syndromes.

  Li H, Hu F, Gale RP, Sekeres MA, Liang Y. Li H, et al. Nat Rev Dis Primers. 2022 Nov 17;8(1):74. doi: 10.1038/s41572-022-00402-5. Nat Rev Dis Primers. 2022. PMID: 36396662 Review.
• Vitamin C Deficiency in Patients With Acute Myeloid Leukemia.

  Ottone T, Faraoni I, Fucci G, Divona M, Travaglini S, De Bellis E, Marchesi F, Angelini DF, Palmieri R, Gurnari C, Giansanti M, Nardozza AM, Montesano F, Fabiani E, Lindfors Rossi EL, Cerretti R, Cicconi L, De Bardi M, Catanoso ML, Battistini L, Massoud R, Venditti A, Voso MT. Ottone T, et al. Front Oncol. 2022 Jun 27;12:890344. doi: 10.3389/fonc.2022.890344. eCollection 2022. Front Oncol. 2022. PMID: 35832559 Free PMC article.